Divarasib, a next-generation, oral KRAS G12C inhibitor, is more potent and selective in vitro than the first-generation KRAS G12C inhibitors sotorasib and adagrasib. In this phase 3, international, Original Article Share on Divarasib as Compared with Sotorasib or Adagrasib in...
Divarasib in Previously Treated Advanced KRAS G12C–Mutated NSCLC Patients with previously treated advanced KRAS G12C–mutant non–small cell lung cancer (NSCLC) had improved progression-free and overall survival and saw improved disease control when treated with the next-generation KRAS-targeted therapy divarasib, according...
Roche announced pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated...
Dr Ferdinandos Skoulidis - The University of Texas MD Anderson Cancer Center, Houston, USA Prof Ferdinandos Skoulidis speaks to ecancer about the primary analysis of the phase III Krascendo 1 trial, which compared divarasib, a next-generation KRAS G12C inhibitor, with...
N Engl J Med ESMO Congress 2026: Next-generation KRAS inhibitor outperforms rivals in lung cancer October 26, 2026 Clinical takeaway: Investigational divarasib significantly prolonged both progression-free and overall survival compared with sotorasib or adagrasib in previously treated KRAS G12C-mutated advanced...
https://www.medscape.com/viewarticle/divarasib-beats-approved-kras-inhi… The investigational targeted therapy divarasib extends overall survival in patients with previously treated, advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), outperforming two existing KRAS inhibitors, according to findings from the phase 3 Krascendo 1 trial.
Patients with previously treated advanced KRAS G12C–mutant non–small cell lung cancer (NSCLC) had improved progression-free and overall survival and saw improved disease control when treated with the next-generation KRAS-targeted therapy divarasib, according to researchers from The University of Texas MD...
The investigational KRAS G12C inhibitor prolongs overall survival in previously treated advanced lung cancer vs existing targeted therapies. Experts predict a change in the standard of care The investigational targeted therapy divarasib extends overall survival in patients with previously treated,...
Ben Solomon: New Standard of Care for KRAS G12C Mutation Positive NSCLC / Adagrasib, Ben Solomon, cancer, Divarasib, ESMO2026, ESMO26, Ferdinandos Skoulidis, Ben Solomon/LinkedIn and Ferdinandos Skoulidis/X Ben Solomon: New Standard of Care for KRAS G12C Mutation Positive NSCLC Ben...
Credit: Pixabay/CC0 Public Domain Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS-targeted therapy divarasib, according to researchers from The University of Texas...
